{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-053950","form_type":"8-K","ticker":"VKTX","cik":"0001607678","company_name":"Viking Therapeutics, Inc.","filed_at":"2021-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.303527+00:00","generated_at":"2026-06-28T14:04:15.895675+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Viking Q3 net loss $0.17/share; cash $216M; VK2809 VOYAGE trial ongoing","bullets":["Net loss of $13.2M ($0.17 per share) in Q3 2021 vs $9.3M ($0.13) in Q3 2020.","Cash, cash equivalents and short-term investments of $216.1M as of Sept 30, 2021 ($248.4M at Dec 31, 2020).","Phase 2b VOYAGE trial for VK2809 (NASH) enrolling; initial data expected in 2022.","Phase 1b trial of VK0214 in X-ALD (AMN) underway; top-line results expected in 2022.","Preclinical dual GLP-1/GIP agonists showed up to 27% body weight reduction; clinical development planned."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-053950","json":"https://secwatch.observer/filing/0001564590-21-053950.json","markdown":"https://secwatch.observer/filing/0001564590-21-053950.md","text":"https://secwatch.observer/filing/0001564590-21-053950.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1607678/000156459021053950/0001564590-21-053950-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1607678/000156459021053950/vktx-8k_20211103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T14:04:15.895675+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}